|
Treatment of Parkinson's Disease with a Transdermal Skin Patch Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Treatment of Parkinson's Disease with a Transdermal Skin Patch conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Treatment of Parkinson's Disease with a Transdermal Skin Patch Clinical research trials and Treatment of Parkinson's Disease with a Transdermal Skin Patch health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Treatment of Parkinson's Disease with a Transdermal Skin Patch. Treatment of Parkinson's Disease with a Transdermal Skin Patch Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Treatment of Parkinson's Disease with a Transdermal Skin Patch clinical trial. Participants oftentimes recieve the most expert healthcare available for their Treatment of Parkinson's Disease with a Transdermal Skin Patch condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > Treatment of Parkinson's Disease with a Transdermal Skin Patch  Treatment of Parkinson's Disease with a Transdermal Skin Patch
Treatment of Parkinson's Disease with a Transdermal Skin Patch
For Condition: Parkinson Disease
Status: Completed
Sponsor(s): National Institute of Neurological Disorders and Stroke (NINDS) ,
Synopsis: Patients with Parkinson's disease are missing the chemical neurotransmitter dopamine. This occurs as a result of destructive changes in an area of the brain responsible for making dopamine, the basal ganglia. Muscle tremors, rigidity of movement, shuffling footsteps, droopy posture, and a mask-like expression on the face characterize Parkinson's disease. This study is designed to determine the effects of a new drug, N-9023. The drug acts like dopamine and can be given through a skin patch (transdermal) for treatment of parkinsonian symptoms. The goals of this study are to find out whether N-9023 is useful in treating the signs and symptoms of Parkinson's disease and to determine the best dose of N-9023 that is safe and effective.
Details: The acute safety and antiparkinsonian efficacy of transdermally delivered N-0923 will be evaluated in patients with Parkinson's disease. This dopamine receptor agonist will be administered transdermally under double-blind conditions, in a rising dose paradigm. Antiparkinsonian activity will be quantified by means of standard rating scales. Possible adverse events will be assessed by appropriate clinical and laboratory tests.
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: All patients will carry a diagnosis of Parkinson's Disease based on the presence of a characteristic clinical history and neurological findings. Symptom severity will range from Hoehn & Yahr stage II-IV. Males and females between the ages 30-76 are eligible for the study. Initial emphasis will be on patients who are taking few or no other medications than levodopa for their Parkinson's disease. No presence or history of any medical condition that can reasonably be expected to subject the patient to unwarranted risk. No patients with a history of significant cardiac (myocardial infarction within 12 months prior to study, dysrhythmia; QTc intervals greater than 440 msec). No patients who are convulsive, hepatic, or with renal disorders (exceeding the upper limit of normal values for LFT's and creatinine respectively). No patients with evidence of other serious medical illness, a history of alcohol or drug abuse, those who have participated in an investigational trial within 28 days prior to study, and pregnant or nursing women or anyone not practicing effective means of birth control.
Total Enrollment: 20
Location and Contact Information:
National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 990104; 99-N-0104
Study Start Date: May 5, 1999
Record last reviewed: June 22, 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001931
Other Parkinson Disease Studies:
1. How the loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance
2. Randomized Study of Fetal Neurotransplantation for the Treatment of Parkinson's Disease
3. A Clinical Study to Evaluate a New Investigative Drug for the Treatment of Parkinson's Disease
4. JP-1730 to Treat Parkinson's Disease
5. Randomized Study of the Effects of Glucose on Cognition in Healthy Young and Elderly People and Parkinson's Disease Patients
Related Studies:
Other Parkinson Disease Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Treatment of Parkinson's Disease with a Transdermal Skin Patch
|
|
|
|
|
|
|
|
